{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T11:35:23Z","timestamp":1768563323117,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ijcard.2018.09.060","type":"journal-article","created":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T19:59:11Z","timestamp":1537559951000},"page":"34-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Ranolazine in patients with type 2 diabetes and chronic angina: A cost-effectiveness analysis and assessment of health-related quality-of-life"],"prefix":"10.1016","volume":"273","author":[{"given":"Elaine","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig I.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine G.","family":"Kohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin R.","family":"Weeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2018.09.060_bb0005","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1161\/CIR.0000000000000558","article-title":"Heart disease and stroke statistics-2018 update: a report from the American Heart Association","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.09.060_bb0010","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1477-7525-8-54","article-title":"Mapping of the EQ-5D index from clinical outcome measures and demographic variables in patients with coronary heart disease","volume":"8","author":"Goldsmith","year":"2010","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.ijcard.2018.09.060_bb0015","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1477-7525-7-96","article-title":"Relationship between the EQ-5D index and measures of clinical outcomes in selected studies of cardiovascular interventions","volume":"7","author":"Goldsmith","year":"2009","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.ijcard.2018.09.060_bb0020","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1067\/mhj.2003.37","article-title":"Quality of life and time trade-off utility measures in patients with coronary artery disease","volume":"145","author":"Melsop","year":"2003","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2018.09.060_bb0025","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/01.CIR.0000020688.24874.90","article-title":"Health status predicts long-term outcome in outpatients with coronary disease","volume":"106","author":"Spertus","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.09.060_bb0030","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1161\/CIRCOUTCOMES.108.829523","article-title":"Economic impact of angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial","volume":"2","author":"Arnold","year":"2009","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"10.1016\/j.ijcard.2018.09.060_bb0035","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0828-282X(08)70680-9","article-title":"Cost of illness for chronic stable angina patients enrolled in a self-management education trial","volume":"24","author":"McGillion","year":"2008","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.060_bb0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1471-2261-6-41","article-title":"The impact of diabetes on one-year health status outcomes following acute coronary syndromes","volume":"6","author":"Peterson","year":"2006","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.ijcard.2018.09.060_bb0045","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","author":"Montalescot","year":"2013","journal-title":"Eur. Heart J."},{"issue":"60","key":"10.1016\/j.ijcard.2018.09.060_bb0050","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2012.07.013","volume":"2012","author":"Fihn","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.060_bb0055","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/j.jacc.2014.07.017","volume":"64","author":"Fihn","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.060_bb0060","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/1479164115609028","article-title":"Non-haemodynamic anti-anginal agents in the management of patients with stable coronary artery disease and diabetes: a review of the evidence","volume":"13","author":"Ambrosio","year":"2016","journal-title":"Diab. Vasc. Dis. Res."},{"key":"10.1016\/j.ijcard.2018.09.060_bb0065","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ijcard.2016.06.150","article-title":"Medical treatment of stable angina: a tailored therapeutic approach","volume":"220","author":"Manolis","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.060_bb0070","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1023\/A:1007744109064","article-title":"The antiischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-1","volume":"13","author":"Szwed","year":"1999","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.ijcard.2018.09.060_bb0075","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.jacc.2013.02.011","article-title":"Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects with Chronic Stable Angina)","volume":"61","author":"Kosiborod","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.060_bb0080","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0735-1097(94)00397-9","article-title":"Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease","volume":"25","author":"Spertus","year":"1995","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.060_bb0085","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1161\/CIRCOUTCOMES.110.940502","article-title":"The cost-effectiveness of percutaneous coronary intervention as a function of angina severity in patients with stable angina","volume":"4","author":"Zhang","year":"2011","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"10.1016\/j.ijcard.2018.09.060_bb0090","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","article-title":"Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial","volume":"291","author":"Chaitman","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2018.09.060_bb0095","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jacc.2006.05.044","article-title":"Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial","volume":"48","author":"Stone","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.060_bb0100","series-title":"Red Book Online","author":"Truven Health Analytics Inc","year":"2016"},{"key":"10.1016\/j.ijcard.2018.09.060_bb0105","author":"U.S. Bureau of Labor Statistics, Division of Consumer Prices and Price Indexes"},{"key":"10.1016\/j.ijcard.2018.09.060_bb0110","doi-asserted-by":"crossref","first-page":"f1049","DOI":"10.1136\/bmj.f1049","article-title":"Consolidated health economic evaluation reporting standards (CHEERS) statement","volume":"346","author":"Husereau","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.ijcard.2018.09.060_bb0115","author":"National Institute for Health and Care Excellence"},{"key":"10.1016\/j.ijcard.2018.09.060_bb0120","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1586\/erp.12.40","article-title":"Sativex in multiple sclerosis spasticity: a cost-effectiveness model","volume":"12","author":"Slof","year":"2012","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"10.1016\/j.ijcard.2018.09.060_bb0125","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1161\/CIRCOUTCOMES.108.798462","article-title":"Cost-effectiveness of percutaneous coronary intervention in optimally treated stable coronary patients","volume":"1","author":"Weintraub","year":"2008","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"10.1016\/j.ijcard.2018.09.060_bb0130","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ijcard.2016.02.140","article-title":"A literature review to evaluate the economic value of ranolazine for the symptomatic treatment of chronic angina pectoris","volume":"211","author":"Vellopoulou","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.060_bb0135","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.amjcard.2015.08.002","article-title":"Comparative effectiveness of ranolazine versus traditional therapies in chronic stable angina pectoris and concomitant diabetes mellitus and impact on health care resource utilization and cardiac interventions","volume":"116","author":"Page","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.060_bb0140","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/eurheartj\/ehi495","article-title":"Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes","volume":"27","author":"Timmis","year":"2006","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.09.060_bb0145","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/CIRCULATIONAHA.107.763912","article-title":"Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial","volume":"119","author":"Morrow","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.09.060_bb0150","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.2337\/dc14-2629","article-title":"Effect of ranolazine monotherapy on glycemic control in subjects with type 2 diabetes","volume":"38","author":"Eckel","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcard.2018.09.060_bb0155","series-title":"Ranexa [Package Insert]","year":"2016"},{"key":"10.1016\/j.ijcard.2018.09.060_bb0160","author":"European Medicines Agency"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752731833328X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752731833328X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T09:22:37Z","timestamp":1545902557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016752731833328X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":32,"alternative-id":["S016752731833328X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2018.09.060","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ranolazine in patients with type 2 diabetes and chronic angina: A cost-effectiveness analysis and assessment of health-related quality-of-life","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2018.09.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}